Biofrontera Inc.
Biofrontera Inc.
- Market cap
- $796.65K
Your view on BFRIW
Overview
What the company does, where it operates, and who runs it.
About Biofrontera Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Hermann Luebbert
- Headquarters
- 660 Main Street, Woburn, MA, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Hermann Luebbert
- Headquarters
- 660 Main Street, Woburn, MA, US
Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy.
This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo.
Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Biofrontera Inc.. Starting points for Biofrontera Inc.: EPS -$0.40, beta 0.80 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Biofrontera Inc.. Trailing twelve-month EPS for Biofrontera Inc. stands at -$0.40. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.24 | −$0.01 | −$0.39 | $0.20 |
| Lowest estimate | $0.23 | −$0.01 | −$0.39 | $0.20 |
| Highest estimate | $0.24 | −$0.01 | −$0.39 | $0.20 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | $0.481 | −$0.411 | −$0.901 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $15.80M | $11.00M | $46.15M | $53.47M |
| Lowest estimate | $15.80M | $11.00M | $45.89M | $53.30M |
| Highest estimate | $15.80M | $11.00M | $46.40M | $53.65M |
| Number of analysts | 2 | 1 | 2 | 2 |
| A year ago | $17.10M | $10.08M | $41.70M | — |
| Growth vs a year ago | −7.6% | +9.1% | +10.6% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Biofrontera Inc.. Biofrontera Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ADILAdial Pharmaceuticals, Inc. | Healthcare | Biotechnology | $13.3M | ||
| HCWBHCW Biologics Inc. | Healthcare | Biotechnology | $260,418 | ||
| LUCYInnovative Eyewear, Inc. | Healthcare | Medical - Instruments & Supplies | $6.1M | ||
| SBFMSunshine Biopharma, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $4.7M | ||
| SNOASonoma Pharmaceuticals, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $3.7M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| QMDTQuick-Med Technologies, Inc. | Healthcare | OTC | $11,204 | ||
| RADLYRaia Drogasil S.A. | Healthcare | OTC | $8.8B | ||
| RBIIRising BioSciences, Inc. | Healthcare | OTC | $4,991 | ||
| RCDTFRecordati Industria Chimica e Farmaceutica S.p.A. | Healthcare | OTC | $11.6B | ||
| RGEDFGedeon Richter PLC | Healthcare | OTC | $5.7B | ||
| RLLVFRelevium Technologies Inc. | Healthcare | OTC | $2.0M | ||
| RMRKRimrock Gold Corp. | Healthcare | OTC | $234,228 | ||
| ROTHPharmaRoth Labs, Inc. | Healthcare | OTC | $35,118 | ||
| RPGLFRegent Pacific Group Limited | Healthcare | OTC | $36.5M | ||
| RPRXRoyalty Pharma plc | Healthcare | NASDAQ | $30.5B | ||
| RSCIRedwood Scientific Technologies, Inc. | Healthcare | OTC | $1,872 | ||
| RTEZRest Ez Inc. | Healthcare | OTC | $1.9B | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Biofrontera Inc. executives and directors. Shares of Biofrontera Inc. have traded between $0.02 and $0.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Biofrontera Inc.. Coverage tracks Biofrontera Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Biofrontera Inc.